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Peritoneal dialysis is a form of renal replacement alternative to the hemodialysis. During this treatment, the peritoneal membrane
acts as a permeable barrier for exchange of solutes and water. Continual exposure to dialysis solutions, as well as episodes of
peritonitis and hemoperitoneum, can cause acute/chronic inflammation and injury to the peritoneal membrane, which undergoes
progressive fibrosis, angiogenesis, and vasculopathy, eventually leading to discontinuation of the peritoneal dialysis. Among the
different events controlling this pathological process, epithelial to mesenchymal transition of mesothelial cells plays a main role
in the induction of fibrosis and in subsequent functional deterioration of the peritoneal membrane. Here, the main extracellular
inducers and cellular players are described. Moreover, signaling pathways acting during this process are elucidated, with emphasis
on signals delivered by TGF-𝛽 family members and by Toll-like/IL-1𝛽 receptors. The understanding of molecular mechanisms
underlying fibrosis of the peritoneal membrane has both a basic and a translational relevance, since it may be useful for setup of
therapies aimed at counteracting the deterioration as well as restoring the homeostasis of the peritoneal membrane.
1. Introduction
Peritoneum is a serosalmembrane that forms the lining of the
abdominal cavity. It is composed of a continuous monolayer
of cells of mesodermal origin, the mesothelial cells (MCs).
MCs have an epithelial-like cobblestone shape and cover a
submesothelial region constituted of a thin layer of connec-
tive tissue composed mainly of bundles of collagen fibers
with few fibroblasts, mast cells, macrophages, and vessels [1].
Peritoneum supports the abdominal organs and serves as a
conduit for their blood vessels, lymph vessels, and nerves.
Between parietal peritoneum, covering the abdominal wall,
and visceral peritoneum, covering abdominal viscera, resides
the peritoneal cavity, a virtual space filled of scarce inter-
stitial fluid. This fluid facilitates peristaltic movements of
abdominal viscera. Moreover, peritoneum is relevant for the
control of local and intestinal immunity due to leukocyte
recirculation [2].
Peritoneal membrane can be used as a dialysis membrane
in therapeutic procedures for the treatment of end-stage renal
disease, as an alternative to classical hemodialysis procedure
[3]. Currently, peritoneal dialysis (PD) accounts for more
than 10% of all forms of renal replacement therapy worldwide
[3]. During PD, the peritoneal membrane (PM) acts as a
permeable barrier across which ultrafiltration and diffusion
take place [4]. Continual exposure to hyperosmotic, hyper-
glycemic, and acidic dialysis solutions, mechanical stress
connected to dwelling practice, and episodes of catheter
complications (including peritonitis and hemoperitoneum)
may cause acute and chronic inflammation and injury of the
PM. In these conditions, peritoneum undergoes progressive
fibrosis, angiogenesis, and vasculopathy, eventually leading to
discontinuation of PD.
A main role in the induction of peritoneal fibrosis
during exposure to PD fluids is played by the epithelial to
mesenchymal transition (EMT) of mesothelial cells (MCs),
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namedmore properlymesothelial tomesenchymal transition
(MMT) [5]. The EMT represents a complex phenomenon of
cellular transdifferentiation that converts the epithelial phe-
notype into amesenchymal one, with loss of cell polarization,
disassembly of adherent and tight junctions, and, conversely,
the acquisition of fibroblastic shape and ability to invade.The
EMT process characterizes physiological (i.e., organogenesis,
development, wound healing, and regeneration) as well as
pathological (i.e., fibrosis, tumor progression, andmetastasis)
processes [6].
In this review, we highlight current knowledge about
cellular players and molecular mechanisms triggering PM
fibrosis. In particular, we summarize the evidence supporting
the involvement of EMT in this phenomenon, with emphasis
on the response to signals delivered by TGF-𝛽 family mem-
bers and by Toll-like/IL-1𝛽 receptors, molecules playing a
main role in EMT induction in the PM.
2. Induction of Fibrosis during PD
During practice of PD, modifications of the PM occur vir-
tually in all patients. Signs of peritoneal fibrosis are detected
in 50% to 80% of patients within one to two years on PD
[7]. In many cases, the peritoneal alterations are limited
and result in a simple peritoneal sclerosis (SPS). SPS is
characterized by increased thickness of the submesothelial
space, increased angiogenesis with hyalinizing vasculopathy,
and presence of denuded areas with loss of MCs. In this
form, the entity of fibrosis is generally limited; it correlates
with the length of exposure to PD fluid and is reversible
when PD is interrupted [8]. In some cases, the patients
develop encapsulating peritoneal sclerosis (EPS), which is a
potentially deadly form of peritoneal fibrosis characterized
by severe peritoneal thickening, inflammation, calcifications,
and fibrin deposits [9]. Fibrosis may progress even if the
patient switches to another form of renal replacement and
may evolve in visceral encapsulation with episodes of bowel
obstruction. The pathogenesis of EPS is debated: it is uncer-
tain whether EPS evolves as a progression of SPS or whether
it is a primitive form of sclerosis [10].
3. Cellular Players of Peritoneal Fibrosis
When exposed to a wide range of exogenous or endogenous
inflammatory/profibrotic stimuli, both cellular components
of peritoneum (MCs, macrophages, mast cells dermal fibrob-
lasts, endothelial cells, and resident macrophages) and other
elements of innate and adaptive immunity actively participate
in the induction of the inflammatory response.
In the case of acute peritonitis, a first wave of neutrophils
recruited by chemoattractants of bacterial origin (LPS) is
progressively replaced by a population of mononuclear cells,
composed of monocytes/macrophages and lymphocyte sub-
sets [11]. In this context, IL-6 plays a main role. IL-6 soluble
receptor (s-IL-6R) shed by neutrophils favors, through a pro-
cess called “transsignaling,” the production of chemokines,
including CXCL8 and CCL2, able to recruit mononuclear
cells [12]. Besides directing leukocyte recruitment to inflamed
peritoneum, these chemokines directly target MCs and other
components of the peritoneum, and their inhibition may
limit peritoneal fibrosis [13, 14].
Both MCs and peritoneal macrophages respond to the
first neutrophil wave and the secondary mononuclear cell
predominance producing a wide array of inflammatory
cytokines such as IL-1𝛽, TNF-𝛼, IL-6, and other proin-
flammatory mediators (chemokines, endogenous Toll-like
receptor (TLR) ligands) [15, 16]. At the same time, molecules
with anti-inflammatory activities, such as IL-10 and TGF-
𝛽, are released in the peritoneal cavity. Mast cells have
been demonstrated to play a role in kidney fibrosis through
production of tryptase and chymase [17]. Moreover, their
number is increased in peritoneum, and they produce fibro-
genic factors in a model of peritoneal fibrosis in rats [18].
Besides components of the innate immunity, more recent
studies performed using murine models demonstrated a
main role of T helper 1 (Th1) cell response and of T
lymphocytes expressing IL17A [19–21]. In these conditions,
the presence of IL-6 is particularly relevant since it may shape
the immune response in subacute-chronic conditions. IL-6,
in combination with TGF-𝛽, is the main cytokine involved
in the T helper 17/regulatory T (Th17/Treg) balance [21].
The predominance of IL-6 favors the generation of Th-17
lymphocytes, which produce inflammatory cytokines. On
the other hand, TGF-𝛽 in the absence of IL-6 promotes
the Treg lineage, producing the anti-inflammatory cytokine
IL-10. The modulation of the expression of these cytokines
through biologic antibodies or recombinant cytokines is
an attracting field for the design of new therapies aimed
at counteracting peritoneal EMT and fibrosis [20, 22, 23].
The presence of proinflammatory and profibrotic cytokines
determines the following: (i) the aberrant production of
extracellular matrix (ECM) proteins, such as Fibronectin
(FN) and type I collagen (Coll) in the submesothelial stroma,
(ii) an unbalanced ratio between procoagulant and anti-
coagulant factors (plasminogen activator inhibitor- (PAI-)
1/plasmin), and (iii) an altered production of glycosamino-
glycans and proteoglycans constituting the extracellular fluid,
which are responsible for the lubrication of the two peritoneal
sheets (parietal and visceral) [16]. In particular, during PD,
expression of high molecular weight hyaluronan and decorin
is reduced, whereas low molecular weight hyaluronan and
versican are induced [24, 25]. Differential expression of
glycosaminoglycans and proteoglycans has pathogenic sig-
nificance, since decorinmaymodulate the bioactivity of TGF-
𝛽1, thus directly affecting the entity of peritoneal fibrosis,
whereas hyaluronan fragments have been shown to induce
multiple signaling cascades, cytokine secretion, and matrix
metalloproteases (MMP) activity [26].
Moreover, neoangiogenesis detected in the peritoneal
stroma is duemainly to the effect of VEGF production, whose
levels correlate with alterations in transport rate [27].
4. EMT of MCs as a Main Cause of
Peritoneal Fibrosis
Besides contributing to production of cytokines and other
soluble factors relevant to sustaining and modulating the
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inflammatory reaction,MCs through EMT play a central role
in the alterations of the PM leading to fibrosis. A seminal
study by Ya´n˜ez-Mo´ and collaborators first demonstrated that
EMTofMCs plays a role in the onset of fibrosis in PDpatients
[5]. This study was followed by others, where with the help
of animal models the main characteristics of MC EMT were
elucidated [23, 28–30].
Not all the features ofMCEMTparallel those of epithelial
cells: due to their mesodermal origin, and differently from
“true” epithelia, such as hepatocytes or keratinocytes, MCs
coexpress in basal conditions epithelial and mesenchymal
markers. This may explain their enhanced plasticity. With
respect to epithelial markers, these cells express high amount
of epithelial cytokeratins, such as cytokeratin 8-18, and
proteins of tight and adherens junctions, such as junctional
adhesion molecule 1 (JAM1) and zonula occludens-1 (ZO-
1). E-cadherin has a peculiar distribution in MCs, since
it is expressed both in membrane and in cytoplasm [28].
Similarly to mesenchymal cells, MCs express constitutively
the intermediate filaments vimentin and desmin [2, 5].
The exposure to inflammatory/profibrotic stimuli leads to
a rapid E-cadherin downregulation, which parallels an induc-
tion of N-cadherin (cadherin switch). While E-cadherin
expression is rapidly downregulated, the expression of cytok-
eratins is only gradually lost; thus, transdifferentiated cells
can maintain for long time trace of their origin.
E-cadherin downregulation parallels the induction of
Snail, a master factor of EMT, directly inhibiting the E-
cadherin transcription [5]. At the same time, the expression
of the specificmesothelial differentiation factorWilms tumor
1 (WT1) is reduced [31].
While epithelial features are lost, MCs rapidly gain
expression of molecules related to EMT, such as 𝛼-SMA
and FSP1. Moreover, MCs produce high levels of PAI-1,
which plays a role in fibrin deposits and fibrosis. Also,
ECM molecules such as FN and Coll are produced, as well
as metalloproteases MMP2 and MMP9, which degrade the
ECM favoring MCs invasive activity [32, 33].
The expression of 𝛼-SMA and FSP1 by MCs makes
them a conceivable main source of myofibroblasts, the cells
endowed with ability to contract the ECM and considered
mostly responsible for the abnormal production of ECM
in fibrosis of all organs [34, 35]. The myofibroblast in a
fibrotic organ is thought to emerge by the activation and
modification of different cellular components: lineage tracing
studies demonstrated that epitheliamay take a role in the gen-
eration ofmyofibroblasts in fibrotic kidney and lung, whereas
endothelium is relevant in the production of myofibroblasts
in heart through a process called Endothelial toMesenchymal
Transition (EndMT) [36–38].
Myofibroblasts are absent in normal peritoneum,whereas
they are found in PM of patients undergoing PD or in
mice exposed to PD fluids [28, 29]. In mice exposed to PD
fluid, it has been demonstrated that myofibroblasts found
in the PM have different origins, including resident dermal
fibroblasts, endothelial cells, bone marrow derived cells, and
MCs [23]. Cells coexpressing cytokeratin (as MCs marker)
and FSP1 or 𝛼-SMA (as myofibroblast markers) invade the
submesothelial stroma, where they take a role in regulating
mesothelial thickness, angiogenesis, leukocyte chemotaxis,
and perturbation of ultrafiltration function [23, 28, 39].
Interestingly, once the EMT-inducing stimuli have been
removed, transdifferentiated MCs tend to maintain their
“mesenchymal” state (Strippoli, unpublished). This observa-
tion, essentially based on in vitro studies, deserves further
analyses since EMT reversal, the phenomenon named Mes-
enchymal to Epithelial Transition (MET), is a mechanism
of peritoneal recovery that may take place in vivo. During
mechanical or biochemical stresses including PD, areas of
PM become devoid of cells. In these conditions, floatingMCs
(that have suffered a “bona fide” EMT) may reattach and
restore cell-to-cell contacts, undergoing MET [40]. Interest-
ingly, these mesenchymal-like MCs may be isolated from
PD fluids and cultured in vitro. Upon exposure to soluble
factors or inhibition of specific pathways, they may partially
reacquire an epithelial-like state [32, 41, 42].
5. Extracellular Inducers of Fibrosis
5.1. Factors Related to Dialysis Fluid Bioincompatibility and
Uremia. Nonphysiologic characteristics of conventional PD
fluid, such as hypertonicity, the presence of high concentra-
tions of glucose and lactate, and acidic pH, are associatedwith
production of inflammatory cytokines and other molecules.
High glucose (HG) itself may induce a proinflammatory
and profibrotic reaction [43]. Many lines of evidence suggest
that the local injury induced by classical glucose-based PD
fluids is mediated, at least in part, by the presence of glucose
degradation products (GDPs) and by the acidic pH. GDPs
through the formation of advanced glycation-end products
(AGEs) may stimulate the production of extracellular matrix
components (ECM) as well as the synthesis of profibrotic and
angiogenic factors [11, 44]. Several studies have demonstrated
the appearance of AGEs in the peritoneal effluents of PD
patients, which correlated with the time on PD treatment.
Biopsy studies have confirmed the accumulation of AGEs in
the peritoneal tissues of PD patients. AGEs accumulation is
associated with fibrosis and ultrafiltration dysfunction [11].
AGEs accumulate also in condition of prolonged hyper-
glycemia not related to PD practice, such as in patients with
diabetes mellitus and during kidney diseases [45]. Uremia
per se is sufficient for inducing fibrosis in peritoneum, which
is further increased when uremic patients undergo PD [46–
48]. Various uremic solutes have been characterized. Among
them, indoxyl sulfate, a derivative from tryptophan, plays a
role in inducing fibrosis in kidney via ROS generation and
TGF-𝛽 production [49].
The use of solutions with neutral pH andwith low content
of GDPs may represent a potential strategy to attenuate some
of the PD-related adverse effects.
5.2. Release of Bacterial Molecules and TLR Ligands. Besides
factors related to bioincompatibility of PD fluid, other
inflammatory stimuli are linked to events connected to
catheterization, such as hemoperitoneum and peritonitis.
Both Gram-positive and Gram-negative bacteria may play a
role in PM injury during PD. Administration of LPS in mice
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peritoneum induces production of inflammatory cytokines
and chemokines and PM damage [50, 51].
Besides inducing a response mediated by Toll-like recep-
tor (TLR) 4, LPS may take a role in the release of HMGB1,
ubiquitous nonhistone nuclear protein capable of activating
innate immune response through engagement of TLRs [50].
MCsmay sense bacterial pathogens also through cytoplasmic
Nod-like receptors, which may also induce production of
inflammatory cytokines and chemokines [52]. Also, frag-
ments of hyaluronic acid released during inflammation can
induce EMT inMCs through engagement of TLRs [16, 53, 54].
5.3. TGF-𝛽1 and Other Cytokines. Among different cytokines
and inflammatory mediators elicited during peritoneal
inflammation, TGF-𝛽1 is considered the main mediator of
peritoneal fibrosis. TGF-𝛽1 belongs to a family of growth fac-
tors that includes TGF-𝛽s, activins, and bone morphogenic
proteins (BMPs) [55, 56]. Among all the members, TGF-
𝛽1 and BMP-7 are key determinant factors in peritoneal
cell plasticity and, in particular, the predominance of one
or the other may determine the epithelial or mesenchymal
phenotype of MCs. TGF-𝛽1 is present in fluids from patients
undergoing PD and its levels correlate with deterioration
of peritoneal membrane [57]. The role of TGF-𝛽1 has been
demonstrated in animal models, in which the intraperitoneal
injection of adenovirus carrying TGF-𝛽1 gene induced a
peritoneal fibrosis similar to that induced upon exposure to
PD fluids [29]. In a mouse model of peritoneal fibrosis, TGF-
𝛽1 blocking peptides preserved the peritoneal membrane by
PD fluid induced damage [23].
The epithelial-like phenotype of MCs, together with their
metastability and plasticity, is the result of a balance between
constitutively secreted factors (including TGF-𝛽1 and its
“counteracting” BMP7, whose expression has been shown
to interfere with fibrogenic activity of TGF-𝛽1) and other
extracellular stimuli [41, 43, 58]. In this regard, BMP7/TGF-
𝛽1 balancemay be altered by other cytokines producedduring
the inflammatory response. For example, CTGF is produced
in response to TGF-𝛽1 and inhibits BMP7 effects [59]. Also,
gremlin concentration in the peritoneal effluent correlated
with measures of peritoneal membrane damage and may
modulate BMP7-mediated effects [60]. HGF may stabilize
the epithelial phenotype inhibiting EMT in MCs [43]. EGF
which supports the epithelial state in some experimental
systems, fostering EMT, and invasion in others has been
recently demonstrated to promote peritoneal fibrosis through
a cross talk with TGF-𝛽 mediated signals [61]. Besides
these inflammatory mediators, many other cytokines that
cooperate in peritoneal EMT/fibrosis induction (i.e., IL-1𝛽,
IL-6, and TNF-𝛼, VEGF, and endothelin-1) are secreted by
MCs and other cells in peritoneum [16, 62].
6. Molecular Mechanisms of EMT and Fibrosis
The complexity of proteome reprogramming occurring dur-
ing EMT-MET dynamics, often involving dysregulation of
specific differentiation processes, suggests the occurrence
of cell-specific molecular mechanisms driving EMT and
fibrosis [63]. Moreover, the molecular mechanisms driving
EMT in different processes (i.e., embryogenesis or tumor)
may be different even in the same cell type. In the case of
the MCs, only a limited number of studies focused on the
understanding of molecular mechanisms underlying EMT
induction, compared to other experimental systems. Cell
specificity is evident in the case of HGF, a cytokine which is
generally considered a “pro-” EMT factor, whereas in MCs it
has an anti-EMT activity [43, 64]. To complicate the picture,
the same pathway may induce both pro-EMT and anti-EMT
effects depending on the experimental conditions.This is the
case of p38 MAPK, which is a main inducer of inflammatory
cytokine production, thus potentially favoring EMT, but
also promoting E-cadherin expression and the epithelial-
like phenotype in MCs [65, 66]. The study of the role of a
specific signaling pathway has been often performed using
pharmacological inhibitors. Although the interpretation of
the results obtained should be carefully evaluated considering
the “caveat” of a possible lack of specificity, the “pharmaco-
logical approach” is especially relevant from a translational
point of view, since it is possible to hypothesize the design of
pharmacological treatments designed to specifically preserve
or recuperate the PM homeostasis in PD patients.
6.1. TGF-𝛽1 Induced Signaling Pathways. With TGF-𝛽1 being
the main factor controlling fibrosis in all organs, it is not
a wonder whether the main signaling pathways responsible
for EMT induction in MCs are induced by this cytokine.
Signaling pathways induced by TGF-𝛽1, as well as TGF-𝛽
family members, are generally divided into Smad-dependent
and Smad-independent ones. TGF-𝛽 factors signal via het-
erodimeric serine/threonine kinase transmembrane receptor
complexes. The binding of the ligand to its primary receptor
(receptor type II) allows the recruitment, transphosphoryla-
tion, and activation of the signaling receptor (receptor type
I). Receptor type I of TGF-𝛽1, or activin receptor-like kinase
5 (ALK5), is then able to exert its serine-threonine kinase
activity phosphorylating Smad2 and Smad3. Receptor type I
of BMP-7 (ALK3) phosphorylates instead Smad1, Smad5, and
Smad8. Upon phosphorylation, they form heterodimers with
Smad4, a commonmediator of all Smad pathways [15, 55, 56,
67].The resulting Smad heterocomplexes translocate into the
nucleus where they bind directly toDNA and activate specific
target genes (Figure 1). A third group of Smads composed of
Smad6 and Smad7, called also inhibitory Smads, limit BMP-
7- and TGF-𝛽1-triggered Smad signaling, respectively, by
preventing the phosphorylation and/or nuclear translocation
of Smad2/3 or Smad1/5/8 complexes and by inducing their
degradation through the recruitment of ubiquitin ligases [55,
56, 67].
The role of Smad3 signaling in TGF-𝛽1 induced EMT and
fibrosis is demonstrated in vivo in Smad3 knockout mice,
which are protected from peritoneal fibrosis, show reduced
collagen accumulation, and display attenuated EMT [39]. On
the other hand, Smad2 may play an antagonistic role in the
EMT process in vivo. Data in peritoneum are lacking; how-
ever Smad2 deficiency increases EMT in keratinocytes and
hepatocytes [68, 69]. Despite their relevance in EMT/MET
induction, the transcriptional activity of Smads alone is low,
compared to other transcription factors: they display their
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Figure 1: The epithelial/mesenchymal status of MCs is due to the balance of signals delivered by multiple receptors. Stimuli promoting
EMT are delivered by TGF-𝛽 in cooperation with inflammatory cytokines and other mediators such as IL-1𝛽, IL-6, TLR ligands, AGEs, and
angiotensin. Smad2/3 pathway plays a main role in combination with ERK1/2 and NF-𝜅B pathway and all converge on the expression of Snail,
the master gene of EMT. Integrin activation promotes the induction of conformational changes and the invasivity of MCs. On the other hand,
signals delivered by BMP7 and HGF favor the epithelial phenotype through the activation of Smad1/5/8 and the inhibition of the Smad2/3
signaling. Also, signals delivered by cell-to-cell confluency (E-cadherin omotypic junctions) may lead to predominance of p38 MAPK over
ERK1/2 and to the inhibition of NF-𝜅B activity. Caveolin-1 organizes signaling platforms favoring the stability of membrane receptors and
inhibiting the Ras/MEK/ERK1/2 pathway.
activity when other transcription factors such as those from
Snail, bHLH, or NF-𝜅B families are present [70].
Targeting Smad signaling by inhibitory Smad7 blocks
EMT and reduces peritoneal fibrotic lesions [71]. Moreover,
HGF and BMP-7 display their effect of EMT inhibition
limiting Smad2/3 activity in MCs (Figure 1) [43, 58].
Indeed, HGF may interfere with TGF-𝛽1 mediated EMT
inducing the expression of the transcriptional corepressor
SnoN, which interacts with activated Smad2/4 complex and
blocks the expression of Smad-dependent genes [72]. BMP-
7 inhibitory effect on EMT is dependent on the activation of
Smad1/5/8 proteins that counteract TGF-𝛽 activated Smad2/3
activity [58].
MCs constitutively express BMP-7 and display basal
activation of Smad1/5/8, which contribute to themaintenance
of the epithelial-like phenotype. EMT induction by TGF-𝛽1
results in BMP-7 downregulation and inactivation of BMP-7-
specific signaling [58].
TGF receptors may also activate signaling pathways
independently of Smads (Figure 2) [55, 73]. Mitogen acti-
vated protein kinases (MAPKs), Rac and Rho GTPases,
phosphatidyl inositol 3 kinase (PI3Kinase)/Akt pathways
are relevant in different cellular function elicited by TGF-
𝛽1 in different EMT experimental systems. TGF-𝛽 induced
MEK/ERK1/2 is particularly relevant in EMT and fibrosis
[74]. TGF-𝛽RImay induce ERK1/2 pathway through tyrosine
phosphorylation of ShcA adaptor protein and subsequent
recruitment of Grb2/Sos complex [75]. In MCs, inhibition
of the MEK/ERK1/2 pathway limited EMT induced by TGF-
𝛽1 in combination with IL-1𝛽, a cytokine mimicking an
inflammatory stimulus, and induced MET in MCs from PD
patients that had undergone EMT in vivo [32]. Moreover,
pharmacological inhibition ofMEK/ERK1/2 pathway rescued
E-cadherin andZO-1 altered expression, reducedfibrosis, and
restored peritoneal function in mice exposed to PD fluids
[28].
Interestingly, TGF𝛽 inducedMEK/ERK1/2 pathwaysmay
alternatively enhance or limit Smad activities.
ERK1/2 may phosphorylate R-Smads in their linker
region, thus inhibiting nuclear translocation and transcrip-
tional activity [76]. More recently, it has been observed
that ERK1/2 phosphorylation of the linker region of nuclear
localized Smads resulted in increased half-life of C-terminal
Smad2 and Smad3 phosphorylation and increased dura-
tion of Smad target gene transcription [77]. MEK/ERK1/2
pharmacological inhibition in MCs reduced Smad3 activ-
ity in luciferase assays, which correlated with reduced C-
terminus Smad3 phosphorylation. Interestingly, in the same
conditions Smad1/5 luciferase activity was increased, with
increased C-terminus phosphorylation [28]. The intensity of
MEK/ERK1/2 response can be modulated by intracellular
factors. Caveolin-1, the principal marker of caveolae, plasma
membrane specialized structures, limits the intensity of the
EMT response through an effect on TGF-RI internalization
or a direct effect on Ras/MEK pathway [28] (Figure 1).
TGF-𝛽1 may induce p38 and JNKMAPK activation path-
way through activation of TAK1 (TGF-𝛽 activated protein)
[78]. Besides being amain driver of inflammation, p38MAPK
plays a role in the control of cell differentiation and apoptosis
[65].
p38 is stably activated in quiescent MCs and, differently
from ERK1/2, its activation levels are increased in conditions
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Figure 2: Cooperation between signals delivered by TGF-𝛽 and Toll-like/IL-1𝛽 receptors in the EMT of MCs. TGF-𝛽 delivers pro-EMT
signals inducing the Smad2/3 (not described in this figure) and the non-Smad pathways, composed of MEK/ERK1/2 and PI3K pathways.
IL-1𝛽 and TLR ligands activate redundant pathways leading to activation of NF-𝜅B and ERK1/2. Also, pathways able to limit EMT induction,
such as p38, are induced at the same time. Smad2/3 acted as transcription factor in combination with Snail, NF-𝜅B, and AP-1 to induce the
EMT program.
of cellular confluency in MCs [66]. p38 activity maintains
E-cadherin expression in MCs and p38-mediated pathway
modulates the mesenchymal conversion of MCs by a feed-
back mechanism based on the downregulation of ERK1/2,
TAK-1/NF-𝜅B activities (Figure 1) [66]. JNK inhibition leads
to the maintenance of E-cadherin expression and block of
EMT, similarly to ERK1/2 inhibition [66, 79].
Besides p38 and JNK, TAK-1 is an activator of NF-𝜅B.
NF-𝜅B inhibition may limit EMT-related events in MCs [32].
Having a wide effect on TGF-𝛽1 induced pathways, it is not
surprising that TAK-1 inhibition may induce EMT reversal
in MCs from PD patients [42].
Among the non-Smadmechanisms involved in EMT, also
PI3K/Akt pathway has been extensively studied [80]. PI3K
activates Akt through phosphorylation at serine 473. Once
activated, Akt has multiple actions including the activation of
mammalian TOR complex 1 (mTORC1) and mTORC2 [80].
Both complexes are involved in different aspects of EMT
and invasion and are sensible to prolonged treatment with
rapamycin [81]. On the other hand, mTORC2 phosphorylates
and activates Akt. Treatment with rapamycin abrogated
transition response, such as induction of 𝛼-SMA expres-
sion, in Smad3 deficient mice [39]. Moreover, it induced
stabilization of 𝛽-catenin, another factor implicated in EMT
induction [80]. Interestingly, rapamycin inhibited in the same
experimental system hypoxia-induced VEGF expression and
angiogenesis [82].
Both Smad and non-Smad pathways converge on acti-
vation of Snail, the master factor of EMT. Snail is a direct
inhibitor of E-cadherin expression [83]. Moreover, Snail
inhibits the expression of other proteins associated with
cell junctions, such as claudins and occludin, with knock-
on effects on the expression of other proteins such as met-
alloproteinases, integrins, and ECM proteins [84]. Besides
Snail, also Slug (Snail2), ZEB1-2, and members of the basic
helix-loop-helix (bHLH) family, such as Twist and E47, play
a role in repressing E-cadherin expression and inducing
EMT. They often have some tissue specificity but similar
mechanism of action [85]. Snail is strongly induced in MCs
upon treatment with TGF-𝛽1. Immunofluorescence analyses
show that Snail has a distribution mainly nuclear: this sug-
gests that mechanisms favoring cytoplasmic accumulation
are probably inactive in MCs [28]. Inhibition of Smad3,
MEK/ERK1/2, and NF-𝜅B results in reduced Snail expression
in MCs [32, 39]. Compared to Snail, Slug is faintly induced
in MCs treated with TGF-𝛽1, whereas Twist is not induced
by the same stimulus (Strippoli, unpublished). Interestingly,
p38 inhibition parallels Snail inhibition in MCs, whereas
induction of Twist is observed [66].
6.2. TLR Ligands Induced Signaling Pathways. During
inflammatory EMT, signals elicited by mediators of
inflammation cooperate with pathways elicited by activation
of TGF-𝛽 (Figure 2). This is particularly relevant in the
Stem Cells International 7
case of peritoneum, which may undergo episodes of acute
inflammation as in the case of bacterial peritonitis due to
catheter implantation. In the case of PD dysfunction induced
by high glucose or the presence of AGEs, peritoneum
undergoes subacute inflammatory alterations, but the
molecular mechanisms of damage are often similar.
Human MCs express ligands for both Gram-positive
and Gram-negative TLR ligands, such as TLR1, TLR2, and
TRL5, but not TLR4 [86]. TLRs have a cytoplasmic signaling
domain homologous to that of IL-1 receptor (IL-1R), called
the Toll/IL-1R domain [87].
Ligand binding to Toll-like receptor (TLR)/IL-1R family
members results in the association of MyD88 with the
cytoplasmic tail of receptors; this then initiates the signaling
cascade that leads to the activation of NF-𝜅B and MAPKs
[87]. Besides IL-1 and TLR ligands, also signaling from AGEs
to their receptors RAGEs converges on NF-𝜅B and MAPK
pathways (Figure 2) [88]. Moreover, signals delivered by IL-
1/TLR ligands affect signaling from other pathways relevant
in EMT induction, such as IL-6. IL-1𝛽 induces IL-6, and
this cytokine may amplify IL-1 response in macrophages and
synovial fibroblasts [89].
In MCs, IL-1𝛽 is a much stronger inducer of NF-𝜅B
response than TGF-𝛽1, and their costimulation generates an
additive response. Inhibition ofNF-𝜅Bblocks EMT induction
upon TGF-𝛽1/IL-1𝛽 costimulation and partially reverses in
vivo EMT in MCs from PD patients [32]. In the same cells,
NF-𝜅B nuclear translocation and transcriptional activity is
enhanced by MEK-ERK1/2 pathway and is inhibited by
p38 [66]. NF-𝜅B controls Snail and Twist expression and
cooperates with Snail in inducing FN transcription [32,
90, 91]. Moreover, NF-𝜅B is a transcriptional inducer of
cyclooxygenase-2 (COX-2), amainmediator of inflammation
[88]. Inhibition of COX-2 with celecoxib resulted in reduced
fibrosis and in partial recovery of ultrafiltration in mice
exposed to PD fluids [92]. Interestingly, Twist is increased
in MCs exposed to high glucose (probably due to NF-𝜅B
activation) in vitro and in the PM of mice exposed to high
glucose PD fluids, and it is linked to MMP9 to MMP9
production and MCs invasion [33].
Overall, it is not surprising that inhibition of NF-𝜅B and
ERK1/2 pathways leads to block and reversal of EMT.
6.3. Noncoding RNA. The discovery of noncoding RNA
unveiled a new layer of regulation of cellular function.
Noncoding-miRNAs selectively bind mRNA, thus inhibiting
their translation or promoting their degradation. Accumulat-
ing evidence shows that miRNAs regulate diverse biological
processes, including cell proliferation, differentiation, and
apoptosis [93, 94]. Recent studies have defined a large
number of miRNAs associated with EMT and controlling the
expression of EMTmaster transcription factors, suggesting a
possible role also in peritoneal fibrosis.
In particular, miR29b and miR30A repress Snail1 expres-
sion [95, 96]. Moreover, members of the miR-200 family and
miR-205 repress the translation of ZEB1 and ZEB2 miRNA.
Notably, ZEB proteins repress the expression of miR-200
[97]. Interestingly, in hepatocyte cellularmodels Snail directly
represses the miR-200c expression [98].
Studies on the role of noncoding RNA have been con-
ducted mainly on experimental models of tumor EMT.
Considering nontumoral experimental setting, studies have
been performed mainly on experimental models of kidney
and lung fibrosis. With regard to chronic progressive kidney
disease, the roles of miR-21, miR-29, and miR-200 have been
best established [99]. A mouse model of pulmonary fibrosis
identified miR-31 as a direct modulator of integrin 𝛼5 and
RhoA, proteins involved in migration and ECM deposition
[100].
On the other hand, only a few data have accumulated
so far on EMT/fibrosis of the peritoneum. PD-related peri-
toneal fibrosis is associated with a loss of miR-29b, and
intraperitoneal delivering of plasmid expressing this miRNA
in mice inhibited peritoneal fibrosis through an effect on
TGF-𝛽/Smad3 pathway [101]. Interestingly, expression of dif-
ferent miRNAs including miR-15a, miR-17, miR-21, miR-30,
miR-192, and miR-377 from dialysis effluent correlated with
peritoneal transport alterations in PD patients, suggesting
a role of miRNA in PM damage [102]. In another study
performed using MCs from effluent of patients undergoing
PD, miRNA200c levels were found reduced in MC from
PD patients [103]. A negative feedback mechanism involving
TGF-𝛽, miR-9-5p, NADPH oxidase 4 (NOX4), and playing a
role in fibrosis of themesothelialmembrane has been recently
described [104].
Besides miRNA, other noncoding RNAs (ncRNA) are
abundantly transcribed in all cell types. Long noncoding
RNAs can exert their effects on biological processes through a
variety of mechanisms and can be involved in the pathophys-
iology of several diseases, including cancer and pulmonary
fibrosis [105, 106]. Concerning peritoneal fibrosis, it has been
recently reported that three lncRNAs target distinct mRNAs
(Dok2, Ier3, HSP72, Junb, and Nedd9) involved in tissue
inflammation and fibrosis [107]. Overall, the role of lncRNA
in MCs EMT deserves future studies.
7. Conclusions
In the last years, the decrease in incidence rate of catheter
complications coupled to the increased biocompatibility of
dialysis solutions reduced the progressive damage to the PM
during peritoneal dialysis. However, the incidence of peri-
toneal membrane problems remains high. To this purpose,
current challenges are both the discovery of biomarkers (that
could allow constantly monitoring the state of PM) and
the understanding of molecular events underlying peritoneal
damage in order to preserve or restore a peritoneal function.
Thus, the study of molecular mechanisms involved in peri-
toneal fibrosis has both a basic and a translational relevance,
appearing essential for the setting of more efficient therapies.
Furthermore, it may conceivably be relevant in the possible
treatment of other pathological conditions involving peri-
toneal fibrosis, such as postsurgical adhesions and peritoneal
fibrosis induced by drugs, and peritonealmetastases [49, 108].
More efforts are needed to better elucidate the MCs
molecular response to inflammatory/fibrogenic signals. Inhi-
bition of main extracellular mediators as well as of specific
players in the cascade of events triggered by TGF-𝛽 and by
8 Stem Cells International
TLR/IL-1𝛽 could represent possible drugs that can simulta-
neously affect multiple target genes. Moreover, the possible
control of the levels of particular ncRNAs, for example, by
simple antagomiRs approaches, could conceivably guarantee
the specific regulation of gene expression for more targeted
therapies.
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